Michael McMurray
Management
Yes, thanks, Stephen. It’s Michael. I’ll take that question and maybe just to kind of back this at the beginning of the year, so at the beginning of the year, we expected to improve our composites business financial performance on the order of about $20 million to $30 million which we said was going to be largely driven by pricing. On our call last quarter, we upgraded that to kind of the high end. So, let’s call it $30 million and then on this call, we have upgraded our outlook for the composites business to be about $40 million year-on-year largely driven by pricing, but we are also seeing some benefit from excellent manufacturing execution as well. And then, from a pricing perspective again, five consecutive quarters of progress, you are right, we have about 50% of our volumes are in fixed price contracts. Those contracts tend to get negotiated in the fourth quarter of every year. I think it’s probably a little bit too early to give any flavor around what we expect. Although I’d say that we expect to make progress.
Stephen Kim – Barclays Capital: Great, that’s very helpful. Appreciate that. Second question relates to the insulation segment which – thanks for your comments about how the incrementals are going to moving in 4Q and results for the year, that’s helpful and I think you attributed the fact that you are going to see a lower incremental in the fourth quarter than you had in the third quarter. I guess, an implication there was inventory build, because you said, I guess you are going to have some curtailments in 4Q I guess, just generally, what seems to me that inventory, kind of store insulation, I mean the stuff is very difficult to – it take up trends than a room and what not. And so, I was curious, how big of a deal was that? And to the degree, there was any inventory build, was it intentional or was it a reflection of some softness in the market on the demand side that that happened? So, if you could just give a little flavor about this curtailment that affects the incremental, that would be interesting. Thanks.